WRF
IPXL

Waddell & Reed Financial’s Impax Laboratories, Inc. IPXL Stock Holding History

Waddell & Reed Financial’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-130,000
Closed -$2.64M – 575
2017
Q3 		$2.64M Sell
130,000
-52,500
-29% -$1M 0.01% 492
2017
Q2 		$2.94M Buy
+182,500
New +$2.7M 0.01% 502

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Waddell & Reed Financial's IPXL Position: Q4 2017 in Review

Waddell & Reed Financial sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 130,000 shares — an estimated $2.64M sold.

Waddell & Reed Financial first reported a position in IPXL in Q2 2017 and held it in 2 quarters. The position peaked at $2.94M in Q2 2017. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

  • Waddell & Reed Financial reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
  • Waddell & Reed Financial sold 130,000 Impax Laboratories, Inc. shares in Q4 2017, an estimated $2.64M.
  • Waddell & Reed Financial first reported a position in Impax Laboratories, Inc. in Q2 2017 and held it in 2 quarters.
  • Waddell & Reed Financial's Impax Laboratories, Inc. position peaked at $2.94M in Q2 2017.
  • 200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Waddell & Reed Financial's 13F filing for Q4 2017, filed 14 Feb 2018.